rs28364997

Variant summary

Our verdict is Likely benign. The variant received -3 ACMG points: 0P and 3B. BP4_ModerateBS1_Supporting

The NM_001044.5(SLC6A3):​c.1676C>T​(p.Ala559Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00123 in 1,614,020 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 15/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. A559T) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.00057 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0013 ( 1 hom. )

Consequence

SLC6A3
NM_001044.5 missense

Scores

1
18

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:6B:1

Conservation

PhyloP100: 0.526

Publications

74 publications found
Variant links:
Genes affected
SLC6A3 (HGNC:11049): (solute carrier family 6 member 3) This gene encodes a dopamine transporter which is a member of the sodium- and chloride-dependent neurotransmitter transporter family. The 3' UTR of this gene contains a 40 bp tandem repeat, referred to as a variable number tandem repeat or VNTR, which can be present in 3 to 11 copies. Variation in the number of repeats is associated with idiopathic epilepsy, attention-deficit hyperactivity disorder, dependence on alcohol and cocaine, susceptibility to Parkinson disease and protection against nicotine dependence.[provided by RefSeq, Nov 2009]
SLC6A3 Gene-Disease associations (from GenCC):
  • classic dopamine transporter deficiency syndrome
    Inheritance: AR Classification: DEFINITIVE, STRONG, MODERATE Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, G2P
  • SLC6A3-related dopamine transporter deficiency syndrome
    Inheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
  • parkinsonism-dystonia, infantile
    Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Likely_benign. The variant received -3 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.10948989).
BS1
Variant frequency is greater than expected in population nfe. GnomAd4 allele frequency = 0.000571 (87/152334) while in subpopulation NFE AF = 0.00106 (72/68026). AF 95% confidence interval is 0.000861. There are 0 homozygotes in GnomAd4. There are 38 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
SLC6A3NM_001044.5 linkc.1676C>T p.Ala559Val missense_variant Exon 13 of 15 ENST00000270349.12 NP_001035.1 Q01959

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
SLC6A3ENST00000270349.12 linkc.1676C>T p.Ala559Val missense_variant Exon 13 of 15 1 NM_001044.5 ENSP00000270349.9 Q01959
SLC6A3ENST00000713696.1 linkc.1590C>T p.Arg530Arg synonymous_variant Exon 13 of 15 ENSP00000519000.1

Frequencies

GnomAD3 genomes
AF:
0.000578
AC:
88
AN:
152216
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.000241
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000196
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.000207
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00106
Gnomad OTH
AF:
0.000959
GnomAD2 exomes
AF:
0.000530
AC:
133
AN:
250852
AF XY:
0.000471
show subpopulations
Gnomad AFR exome
AF:
0.000124
Gnomad AMR exome
AF:
0.0000868
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00105
Gnomad OTH exome
AF:
0.000816
GnomAD4 exome
AF:
0.00130
AC:
1893
AN:
1461686
Hom.:
1
Cov.:
33
AF XY:
0.00117
AC XY:
848
AN XY:
727162
show subpopulations
African (AFR)
AF:
0.0000896
AC:
3
AN:
33476
American (AMR)
AF:
0.000224
AC:
10
AN:
44718
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26136
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39698
South Asian (SAS)
AF:
0.0000696
AC:
6
AN:
86254
European-Finnish (FIN)
AF:
0.0000188
AC:
1
AN:
53276
Middle Eastern (MID)
AF:
0.000348
AC:
2
AN:
5750
European-Non Finnish (NFE)
AF:
0.00164
AC:
1828
AN:
1111982
Other (OTH)
AF:
0.000712
AC:
43
AN:
60396
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.480
Heterozygous variant carriers
0
108
215
323
430
538
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
76
152
228
304
380
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.000571
AC:
87
AN:
152334
Hom.:
0
Cov.:
32
AF XY:
0.000510
AC XY:
38
AN XY:
74492
show subpopulations
African (AFR)
AF:
0.000240
AC:
10
AN:
41580
American (AMR)
AF:
0.000196
AC:
3
AN:
15306
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3468
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5186
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4830
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10624
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
0.00106
AC:
72
AN:
68026
Other (OTH)
AF:
0.000949
AC:
2
AN:
2108
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.494
Heterozygous variant carriers
0
4
8
13
17
21
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000917
Hom.:
0
Bravo
AF:
0.000620
TwinsUK
AF:
0.000539
AC:
2
ALSPAC
AF:
0.000519
AC:
2
ESP6500AA
AF:
0.000454
AC:
2
ESP6500EA
AF:
0.000814
AC:
7
ExAC
AF:
0.000412
AC:
50
Asia WGS
AF:
0.000577
AC:
2
AN:
3478
EpiCase
AF:
0.000981
EpiControl
AF:
0.000948

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:6Benign:1
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Uncertain:2Benign:1
Sep 01, 2024
CeGaT Center for Human Genetics Tuebingen
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

SLC6A3: BP4 -

Jul 02, 2025
GeneDx
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Reported as an apparently de novo variant in heterozygous state in male patient with global developmental delay, hypotonia, status epilepticus, and lactic acidosis; however, a second SLC6A3 variant was not identified and additional variants in other genes that may have been responsible for the phenotype were also identified in this patient (PMID: 26931468); Reported in heterozygous state in an individual with bipolar disorder; however, a second SLC6A3 variant was not identified and variant did not segregate with other affected family members (PMID: 10889530); Reported in heterozygous state in two siblings with attention deficit hyperactivity disorder; however, additional clinical information and segregation information was not provided (PMID: 16171832); Reported in heterozygous state in two unrelated patients with autism in published literature; however, the variant was maternally inherited in both cases from unaffected mothers (PMID: 25313507); In silico analysis suggests that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 18614672, 25331903, 20427663, 29559554, 16103889, 16171832, 19590515, 31133547, 34426522, 35317228, 32473160, 33310157, 37238676, 31094705, 37205452, 34000340, 36630507, 34002696, 34104969, 36552823, 36750796, 10889530, 25313507, 38168036, 37987120, 26931468) -

Sep 01, 2016
Eurofins Ntd Llc (ga)
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Inborn genetic diseases Uncertain:1
Mar 09, 2022
Ambry Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The c.1676C>T (p.A559V) alteration is located in exon 13 (coding exon 12) of the SLC6A3 gene. This alteration results from a C to T substitution at nucleotide position 1676, causing the alanine (A) at amino acid position 559 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -

Classic dopamine transporter deficiency syndrome Uncertain:1
Jun 25, 2020
CENTOGENE GmbH and LLC - Guiding Precision Medicine
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

See cases Uncertain:1
Feb 19, 2020
Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Parkinsonism-dystonia, infantile Uncertain:1
Jan 17, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 559 of the SLC6A3 protein (p.Ala559Val). This variant is present in population databases (rs28364997, gnomAD 0.1%), and has an allele count higher than expected for a pathogenic variant. This missense change has been observed in individual(s) with bipolar disorder, attention-deficit hyperactivity disorder (ADHD), speech disfluency, infantile encephalopathy, and/or autism-spectrum disorder (ASD) (PMID: 10889530, 16171832, 19590515, 25313507, 26931468). ClinVar contains an entry for this variant (Variation ID: 290889). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt SLC6A3 protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change affects SLC6A3 function (PMID: 18614672, 20427663, 25313507, 25331903). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.063
BayesDel_addAF
Benign
-0.30
T
BayesDel_noAF
Benign
-0.25
CADD
Benign
9.0
DANN
Benign
0.81
DEOGEN2
Benign
0.16
T
Eigen
Benign
-1.0
Eigen_PC
Benign
-0.98
FATHMM_MKL
Benign
0.082
N
LIST_S2
Benign
0.75
T
M_CAP
Benign
0.076
D
MetaRNN
Benign
0.11
T
MetaSVM
Benign
-0.99
T
MutationAssessor
Benign
0.0050
N
PhyloP100
0.53
PrimateAI
Benign
0.34
T
PROVEAN
Benign
-0.31
N
REVEL
Uncertain
0.43
Sift
Benign
0.70
T
Sift4G
Benign
0.58
T
Polyphen
0.0
B
Vest4
0.65
MVP
0.99
MPC
0.60
ClinPred
0.0098
T
GERP RS
-1.3
Varity_R
0.068
gMVP
0.50
Mutation Taster
=16/84
disease causing

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs28364997; hg19: chr5-1403128; COSMIC: COSV54362428; COSMIC: COSV54362428; API